SNSE Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -- compared to Sensei Biotherapeutics, Inc.'s net margin of 20.83%. Sensei Biotherapeutics, Inc.'s return on equity of -68.55% beat Johnson & Johnson's return on equity of 34.46%.

Sensei Biotherapeutics, Inc. has a consensus price target of $32.50, signalling upside risk potential of 4.48%. On the other hand Johnson & Johnson has an analysts' consensus of $232.50 which suggests that it could fall by -4.12%. Given that Sensei Biotherapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Sensei Biotherapeutics, Inc. is more attractive than Johnson & Johnson.

Sensei Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Sensei Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.12% to investors and pays a quarterly dividend of $1.30 per share. Sensei Biotherapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sensei Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Sensei Biotherapeutics, Inc.'s net income of -$4.9M is lower than Johnson & Johnson's net income of $5.1B. Notably, Sensei Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 21.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics, Inc. is -- versus 6.25x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Picard Medical has a net margin of -- compared to Sensei Biotherapeutics, Inc.'s net margin of --. Sensei Biotherapeutics, Inc.'s return on equity of -68.55% beat Picard Medical's return on equity of --.

Sensei Biotherapeutics, Inc. has a consensus price target of $32.50, signalling upside risk potential of 4.48%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Sensei Biotherapeutics, Inc. has higher upside potential than Picard Medical, analysts believe Sensei Biotherapeutics, Inc. is more attractive than Picard Medical.

Sensei Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sensei Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.

Sensei Biotherapeutics, Inc. quarterly revenues are --, which are larger than Picard Medical quarterly revenues of --. Sensei Biotherapeutics, Inc.'s net income of -$4.9M is higher than Picard Medical's net income of --. Notably, Sensei Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics, Inc. is -- versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.

Tactile Systems Technology, Inc. has a net margin of -- compared to Sensei Biotherapeutics, Inc.'s net margin of 10.27%. Sensei Biotherapeutics, Inc.'s return on equity of -68.55% beat Tactile Systems Technology, Inc.'s return on equity of 9.17%.

Sensei Biotherapeutics, Inc. has a consensus price target of $32.50, signalling upside risk potential of 4.48%. On the other hand Tactile Systems Technology, Inc. has an analysts' consensus of $38.00 which suggests that it could grow by 32.31%. Given that Tactile Systems Technology, Inc. has higher upside potential than Sensei Biotherapeutics, Inc., analysts believe Tactile Systems Technology, Inc. is more attractive than Sensei Biotherapeutics, Inc..

Sensei Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tactile Systems Technology, Inc. has a beta of 0.960, suggesting its less volatile than the S&P 500 by 3.951%.

Sensei Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tactile Systems Technology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics, Inc. pays -- of its earnings as a dividend. Tactile Systems Technology, Inc. pays out -- of its earnings as a dividend.

Sensei Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Tactile Systems Technology, Inc. quarterly revenues of $103.6M. Sensei Biotherapeutics, Inc.'s net income of -$4.9M is lower than Tactile Systems Technology, Inc.'s net income of $10.6M. Notably, Sensei Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Tactile Systems Technology, Inc.'s PE ratio is 34.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics, Inc. is -- versus 2.02x for Tactile Systems Technology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology, Inc. has a net margin of -- compared to Sensei Biotherapeutics, Inc.'s net margin of -67975.42%. Sensei Biotherapeutics, Inc.'s return on equity of -68.55% beat Vir Biotechnology, Inc.'s return on equity of -48.24%.

Sensei Biotherapeutics, Inc. has a consensus price target of $32.50, signalling upside risk potential of 4.48%. On the other hand Vir Biotechnology, Inc. has an analysts' consensus of $16.56 which suggests that it could grow by 118.99%. Given that Vir Biotechnology, Inc. has higher upside potential than Sensei Biotherapeutics, Inc., analysts believe Vir Biotechnology, Inc. is more attractive than Sensei Biotherapeutics, Inc..

Sensei Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vir Biotechnology, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.258%.

Sensei Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics, Inc. pays -- of its earnings as a dividend. Vir Biotechnology, Inc. pays out -- of its earnings as a dividend.

Sensei Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Vir Biotechnology, Inc. quarterly revenues of $240K. Sensei Biotherapeutics, Inc.'s net income of -$4.9M is higher than Vir Biotechnology, Inc.'s net income of -$163.1M. Notably, Sensei Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Vir Biotechnology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics, Inc. is -- versus 61.84x for Vir Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.